A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Recruiting · Phase 3 · NCT06561386
Conditions: Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $15,738
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 1,000
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (drug), Relatlimab (drug), Pembrolizumab (drug), Carboplatin (drug), Pemetrexed (drug), Cisplatin (drug)
- Dates
- Started 2024-10-07; completion 2032-08-04
- Results posted
- Not yet
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $15,738 in research payments for this study in 2025 (9 payments).
Products named: Opdualag
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Estelamari Rodriguez, MD Hematology & Oncology · Miami, FL
- Colleen M. Darnell, M.D. Hematology & Oncology · Edgewood, KY
- John S. Hrom, MD Hematology & Oncology · Hattiesburg, MS
- Katharine E. Thomas, M.D. Medical Oncology · Reno, NV
- Alton J. Walters, MD Internal Medicine · Las Vegas, NV
- Daniel J. Becker, MD Medical Oncology · New York, NY
- Jennifer L. Leddon Hematology & Oncology · Cincinnati, OH
- Coty H. Ho, MD Medical Oncology · Conway, SC
- Mehmet Altan, M.D. Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $3,364
- St Elizabeth Edgewood, KY $2,325
- Childrens Hospital and Research Center at Oakland $1,922
- Renown Regional Medical Center, NV $1,868
- VA New York Harbor Healthcare System Manhattan Campus $1,531
- New Mexico VA Health Care System $1,486
- University of Miami Hospital $1,096
- University of Cincinnati $1,087
- Hattiesburg Clinic Hematology Oncology $1,058
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.